Investor directory

Bay City Capital

Bay City Capital LLC, founded in 1997 and based in California, is a private equity firm that specializes in managing investment funds within the life sciences sector. The firm has overseen six venture funds, which collectively represent $1.5 billion in capital invested across more than 70 companies. Among these funds, five focus on general life sciences, while one is dedicated to the nutrition and agribusiness sectors. Bay City Capital aims to support innovative companies that contribute to advancements in healthcare and related fields.
http://www.baycitycapital.com
https://crunchbase.com/organization/bay-city-capital
https://linkedin.com/company/baycitycapital
https://twitter.com/baycitycapital
https://www.capitaliq.com/CIQDotNet/company.aspx?companyId=19099
https://www.privateequityinternational.com/database/#/profile?id=8138

David Beier

Managing Director

Fred Craves

Managing Director

Carl Goldfischer

Managing Director

Matthew Kronmiller

Vice President

Manuel Lopez-Figueroa

Venture Partner

Susan Vuong

Chief Financial Officer and Chief Compliance Officer

Past deals in South Dakota

Bridge Medicines

Funding Round in 2020
Bridge Medicines LLC offers drug discovery services. It focuses on developing technologies in academic institutions from human proof-of-concept to clinical development. The company develops inhibitors of ENL-YEATS for the treatment of acute leukemias, such as acute myelogenous leukemia and a series of orally active small molecule inhibitors of activated factor XII for the treatment of hereditary angioedema and other inflammatory disorders. Bridge Medicines LLC was founded in 2016 and is based in New York, New York.

Bridge Medicines

Venture Round in 2016
Bridge Medicines LLC offers drug discovery services. It focuses on developing technologies in academic institutions from human proof-of-concept to clinical development. The company develops inhibitors of ENL-YEATS for the treatment of acute leukemias, such as acute myelogenous leukemia and a series of orally active small molecule inhibitors of activated factor XII for the treatment of hereditary angioedema and other inflammatory disorders. Bridge Medicines LLC was founded in 2016 and is based in New York, New York.